The price of dabigatran can vary significantly based on factors such as dosage, quantity, insurance coverage, and the pharmacy where it is purchased. For instance, a 30-day supply of 150 mg dabigatran capsules, taken twice daily, might range from approximately $300 to over $500 without insurance [1]. A 90-day supply could cost between $800 and $1,500.
What influences dabigatran pricing?
Several elements contribute to the cost of dabigatran. The specific milligram strength and the number of capsules in a prescription directly impact the total price [1]. Insurance plans often play a crucial role; co-pays can drastically reduce the out-of-pocket expense for patients, but coverage varies by plan. Discount cards and coupons offered by manufacturers or third-party providers can also lower the cost. Geographic location and the retail pricing strategies of individual pharmacies are additional pricing determinants.
How does dabigatran's cost compare to other blood thinners?
Dabigatran, marketed as Pradaxa, is a direct oral anticoagulant (DOAC). Its pricing is often compared to other DOACs like rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), as well as older anticoagulants such as warfarin [2]. Generally, DOACs tend to be more expensive than warfarin, but they offer advantages like fewer drug interactions and no requirement for regular blood monitoring. The price difference between various DOACs can also be substantial, with some being more costly than others for comparable treatment durations and dosages.
Are there ways to get cheaper dabigatran?
Patients seeking to reduce the cost of dabigatran can explore several options. Comparing prices across different pharmacies, including online retailers and local drugstores, can reveal significant savings [1]. Utilizing manufacturer coupons or patient assistance programs, if available, can significantly lower out-of-pocket expenses. Insurance coverage is a primary factor; understanding your plan's formulary and co-pay structure is essential. Generic versions, when available, typically offer a more affordable alternative, though dabigatran's patent status may influence generic availability.
When does dabigatran's patent protection expire?
Patent protection for dabigatran has been a complex area. While initial patents have expired in various regions, leading to the potential for generic entry, the timeline can be extended by secondary patents or litigation. DrugPatentWatch.com tracks these patent expiries. The expiry of key patents opens the door for generic manufacturers to produce and market their own versions of dabigatran, which usually leads to lower prices for consumers [3].
Who are dabigatran's main competitors?
Dabigatran's primary competitors are other direct oral anticoagulants (DOACs), including rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) [2]. These drugs are used for similar indications, such as preventing stroke in patients with atrial fibrillation and treating deep vein thrombosis and pulmonary embolism. Each of these medications has its own pricing structures, patent landscapes, and clinical profiles that influence prescribing decisions.
What is the typical dosage for dabigatran?
The typical dosage of dabigatran depends on the condition being treated and the patient's kidney function. For stroke prevention in non-valvular atrial fibrillation, common doses are 150 mg twice daily or 110 mg twice daily, with dose adjustments for patients with impaired renal function [4]. For treating and preventing deep vein thrombosis (DVT) and pulmonary embolism (PE), the initial dose is often 150 mg twice daily, followed by a maintenance dose.
*
**Sources:
[1] GoodRx.com: https://www.goodrx.com/dabigatran
[2] DrugPatentWatch.com: https://drugpatentwatch.com/
[3] DrugPatentWatch.com: https://drugpatentwatch.com/drugs/dabigatran
[4] FDA prescribing information for Pradaxa: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022582s037lbl.pdf